NeuroPace, Inc. (NPCE) Guidance & Earnings Results

On 2026-08-11 NeuroPace, Inc. raised guidance: "FY2026 total revenue raised to $99.5-101.5M from $99-101M; FY2026 non-GAAP gross margin raised to 82-83% from 81.5-82.5%; FY2026 non-GAAP operating expenses reiterated at $90-92M; FY2026 Adjusted EBITDA raised to…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

NPCENeuroPace, Inc.Follow NPCE — free

Medical Devices · Healthcare

—

Price chart with a free account

Market cap: 443.1M
P/E TTM: —
Dividend yield: 0.0%
52-week: —
Next earnings: 10 Nov, in 17 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
11 Aug 26	Raised	FY2026 total revenue raised to $99.5-101.5M from $99-101M; FY2026 non-GAAP gross margin raised to 82-83% from 81.5-82.5%; FY2026 non-GAAP operating expenses reiterated at $90-92M; FY2026 Adjusted EBITDA raised to ($7.5)-($8.5)M from prior · full year
12 May 26	Raised	FY2026 revenue guidance raised to $99M-$101M from $98M-$100M; Adjusted EBITDA improved to ($8.5)-($9.5)M from ($9.0)-($10.0)M · full year
3 Mar 26	Reaffirmed	Reiterated 2026 guidance: 20%-22% RNS revenue growth; IGE contribution expected after potential mid-2026 approval. · full year
4 Nov 25	Raised	FY2025 total revenue guidance raised to $97M-$98M (from $94M-$98M); gross margin raised to 76%-77% (from 75%-76%); opex guidance increased to $94M-$95M. · full year
12 Aug 25	Raised	FY25 revenue raised to $94-98M from $93-97M; FY25 gross margin raised to 75-76% from 73-75%; FY25 opex maintained at $92-95M · full year

NeuroPace, Inc. — questions

What guidance did NeuroPace, Inc. give?: On 2026-08-11: "FY2026 total revenue raised to $99.5-101.5M from $99-101M; FY2026 non-GAAP gross margin raised to 82-83% from 81.5-82.5%; FY2026 non-GAAP operating expenses reiterated at $90-92M; FY2026 Adjusted EBITDA raised to ($7.5)-($8.5)M from prior"
When does NeuroPace, Inc. report earnings?: NeuroPace, Inc.'s next earnings report is expected on 2026-11-10.

Every figure on this page comes from NeuroPace, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.